• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Boehringer Ingelheim Pharmaceuticals

Bodyport secures $11.2m to build ‘virtual cardiac clinic’ for your bathroom

August 11, 2020 By Tom Salemi

Bodyport, a company building sensitive sensor technologies into a bathroom scale, secured an $11.2 million Series A round to develop a device that can help detect and manage heart disease by detecting cardiac signals and biomarkers through bare feet. Boehringer Ingelheim Venture Fund (BIVF) led the round in the San Francisco-based startup, adding its capital […]

Filed Under: Cardiovascular, Diagnostics, Digital Health, Featured, Funding Roundup, Health Information Technology Tagged With: Beth Israel Lahey Health, Bodyport, Boehringer Ingelheim Pharmaceuticals

Biopharmaceutical companies pledge more than $1 billion to develop new antibiotics

July 9, 2020 By Chris Newmarker

More than 20 biopharmaceutical companies around the world have pledged more than $1 billion toward the Antimicrobial Resistance (AMR) Action Fund that launched today. Pledges include $100 million from Pfizer and $50 million from Boehringer Ingelheim. An initiative of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the fund’s goal is to bring two to four […]

Filed Under: Featured, Pharmaceutical Tagged With: antibiotics, Antimicrobial Resistance (AMR) Action Fund, Boehringer Ingelheim Pharmaceuticals, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Pfizer, superbugs

Boehringer Ingelheim touts Spiolto Respimat inhaler data

October 2, 2019 By Sean Whooley

Boehringer Ingelheim said yesterday that results from a study of its Spiolto Respimat inhaler showed benefits including improving symptoms and lung function in treating chronic obstructive pulmonary disease. The Spiolto Respimat is a soft-mist inhaler designed for the treatment of airflow obstruction in patients with COPD. A pooled analysis exploring COPD treatment with the tiotropium-based […]

Filed Under: Clinical Trials, Respiratory Tagged With: Boehringer Ingelheim Pharmaceuticals

Sunovion launches inhaled COPD therapy in U.S.

April 3, 2018 By Sarah Faulkner

Sunovion Pharmaceuticals launched its Lonhala Magnair drug in the U.S. for the long-term maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease, the company reported today. Sunovion touts its drug as the first nebulized long-acting muscarinic antagonist approved to treat COPD in the U.S. The product is delivered using the Magnair nebulizer […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Respiratory Tagged With: Boehringer Ingelheim Pharmaceuticals, Sunovion Pharmaceuticals

Brainomix raises $10m for AI stroke imaging tech

April 3, 2018 By Brad Perriello

Brainomix said today that it raised nearly $10 million for the e-ASPECTS stroke imaging technology it’s developing using artificial intelligence. The £7 million round was led by Parkwalk Advisors, joined by existing backers Chimera Partners and Oxford University Innovation Fund and the venture arm of pharma giant Boehringer Ingelheim. Oxford, England-based Brainomix said its tech is […]

Filed Under: Diagnostics, Funding Roundup, Imaging, Neurological Tagged With: Boehringer Ingelheim Pharmaceuticals, Brainomix, Stroke

Boehringer Ingelheim inks outcomes-based contract with pharmacy benefit manager for diabetes drug

January 29, 2018 By Sarah Faulkner

Boehringer Ingelheim has inked an outcomes-based contract with pharmacy benefit manager Prime Therapeutics for its oral Type II diabetes drug, Jardiance. The medication is designed to cut the risk of cardiovascular death in adult patients with Type II diabetes and established heart disease. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Cardiovascular, Diabetes, Pharmaceutical Tagged With: Boehringer Ingelheim Pharmaceuticals

Sunovion wins FDA nod for inhaled COPD therapy

December 6, 2017 By Sarah Faulkner

The FDA has approved Sunovion Pharmaceutical‘s Lonhala Magnair system for the long-term treatment of airflow obstruction in people with chronic obstructive pulmonary disease, the company reported today. The drug-device combo, also known as Sun-101/eFlow, is the first nebulized long-acting muscarinic antagonist approved for the treatment of COPD in the U.S. The system includes a portable nebulizer […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance, Respiratory Tagged With: Boehringer Ingelheim Pharmaceuticals, Sunovion Pharmaceuticals

Boehringer Ingelheim, Anthem partner for largest real-world COPD trial

October 12, 2017 By Sarah Faulkner

As part of a research collaboration launched in 2014, Boehringer Ingelheim and Anthem have partnered to study people with chronic obstructive pulmonary disease in real-world settings to assess how commonly-prescribed drugs may reduce the occurrence of COPD exacerbations. The team, which also includes Anthem’s outcomes research subsidiary HealthCore, plans to investigate whether adding an inhaled corticosteroid to […]

Filed Under: Clinical Trials, Drug-Device Combinations, Pharmaceutical, Respiratory, Wall Street Beat Tagged With: Anthem Inc., Boehringer Ingelheim Pharmaceuticals

Mylan, Theravance’s inhaled COPD therapy proves safe in late-stage trial

July 20, 2017 By Sarah Faulkner

Mylan (NSDQ:MYL) and Theravance Biopharma, Inc. (NSDQ:TBPH) touted safety data yesterday from the late-stage trial of its once-daily inhaled bronchodilator, revefenacin, in patients with chronic obstructive pulmonary disease. If approved, revefenacin would be the first nebulized long-acting muscarinic antagonist on the market for COPD patients in the U.S. Get the full story at our sister site, Drug Delivery Business […]

Filed Under: Clinical Trials, Drug-Device Combinations, Pharmaceutical, Respiratory, Wall Street Beat Tagged With: Boehringer Ingelheim Pharmaceuticals, Mylan, Sunovion Pharmaceuticals, Theravance

Leukemia trial to match patients with drugs based on genetic biomarkers

July 19, 2017 By Sarah Faulkner

The Leukemia & Lymphoma Society said today that its expanding its Beat AML Master trial to include five investigational treatments for acute myeloid leukemia. The trial, which launched in October last year, has enrolled 70 patients and has garnered support by Alexion Pharmaceuticals (NSDQ:ALXN), Boehringer Ingelheim, Celgene (NSDQ:CELG) and Gilead Sciences (NSDQ:GILD), all of which are providing investigational AML treatments. The non-profit […]

Filed Under: Clinical Trials, Oncology, Pharmaceutical, Wall Street Beat Tagged With: alexionpharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Celgene, Gilead Sciences

Nanoparticles: An industry buzzword meets reality

May 31, 2017 By Sarah Faulkner

Young startups backed by nanoparticle tech face a world hurdles before reaching the clinic. It’s been decades since the first innovations with nanotechnology – and experts are asking, “Where are all the drugs?” It’s been more than 20 years since the FDA approved the first nanoparticle drug, Doxil. At the time, nanoparticles were heralded as a […]

Filed Under: Clinical Trials, Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Boehringer Ingelheim Pharmaceuticals, Catalent, Cerulean Pharma Inc., Dicerna Pharmaceuticals, latonatherapeutics

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS